Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Monday’s analyst upgrades and downgrades Add to ...

Subscribers Only

Inside the Market’s roundup of some of today’s key analyst actions

ProMetic Life Sciences Inc.’s (PLI-T) $53-million equity financing is dilute, but it strengthens its balance sheet, according to Canaccord Genuity analyst Neil Maruoka.

However, citing the dilution resulting from the financing and near-term uncertainty related to its plasminogen treatment, Mr. Maruoka lowered his target for the stock and removed ProMetic for Canaccord’s Canadian Focus List.

Report Typo/Error

Follow on Twitter: @daveleeder

 

More Related to this Story

Topics

Next story

loading

Trending

loading

Most popular videos »

More from The Globe and Mail

Most popular